Neurocrine Biosciences (NBIX) EBITDA Margin (2010 - 2026)
Neurocrine Biosciences (NBIX) reported EBITDA Margin of 18.38% for Q2 2026, down 3.86 percentage points from 22.24% a year earlier and down 6.26 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBITDA Margin (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Neurocrine Biosciences' EBITDA Margin came in at 24.96%, up 4.10 percentage points year-over-year; for FY2025, it was 22.70%, down 2.68 percentage points from FY2024.
- EBITDA Margin has a five-year change of +6.29 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at 25.37% in FY2024 (+10.95 pp), 14.42% in FY2023 (-3.35 pp), 17.77% in FY2022 (+7.77 pp) and 10.00% in FY2021 (-6.40 pp).
- The Q2 2026 figure ranks as the lowest quarterly EBITDA Margin since Q1 2025.
- Year over year, EBITDA Margin gained in four of the last eight quarters, with an average year-over-year change of -0.61 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q1 2024 (a gain of 46.45 percentage points); the low point was Q4 2021 (a drop of 40.52 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 24.64% (Q1 2026), 27.11% (Q4 2025) and 31.04% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 39.16% |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 18.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.38% |
| Mar 31, 2026 | 24.64% |
| Dec 31, 2025 | 27.11% |
| Sep 30, 2025 | 31.04% |
| Jun 30, 2025 | 22.24% |
| Mar 31, 2025 | 5.45% |
| Dec 31, 2024 | 23.75% |
| Sep 30, 2024 | 30.59% |
| Jun 30, 2024 | 25.87% |
| Mar 31, 2024 | 20.47% |
| Dec 31, 2023 | 30.30% |
| Sep 30, 2023 | 29.45% |
| Jun 30, 2023 | 17.43% |
| Mar 31, 2023 | -25.93% |
| Dec 31, 2022 | 26.21% |
| Sep 30, 2022 | 23.72% |
| Jun 30, 2022 | 15.60% |
| Mar 31, 2022 | 2.19% |
| Dec 31, 2021 | -9.36% |
| Sep 30, 2021 | 17.40% |
API Access
Neurocrine Biosciences EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();